Safety of and Immune Response to an HIV Vaccine (SF-2 gp120) With or Without MTP-PE/MF59 Adjuvant - Contacts and Locations

Safety of and Immune Response to an HIV Vaccine (SF-2 gp120) With or Without MTP-PE/MF59 Adjuvant

This study has been completed.

Study NCT00001019. Last updated on June 23, 2005. Information provided by National Institute of Allergy and Infectious Diseases (NIAID)

Please refer to this study by its ClinicalTrials.gov identifier: NCT00001019

Locations


United States, Missouri
	St Louis Univ School of Medicine
	St. Louis, Missouri, United States, 63104

United States, Pennsylvania
	Univ of Pennsylvania at Philadelphia
	Philadelphia, Pennsylvania, United States, 19104

United States, Tennessee
	Saint Jude Children's Research Hosp of Memphis
	Memphis, Tennessee, United States, 381052794
	Vanderbilt Univ Hosp
	Nashville, Tennessee, United States, 37232

United States, Washington
	Children's Hospital & Medical Center / Seattle ACTU
	Seattle, Washington, United States, 981050371

Sponsors and Collaborators

National Institute of Allergy and Infectious Diseases (NIAID)

Biocine

Investigators


Study Chair:	Graham B